AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04819451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnesium-Rich Artificial Cerebrospinal Fluid (MACSF)
Description: The Magnesium-Rich Artificial Cerebrospinal Fluid (MACSF) is composed of several qualified clinical intravenous injections according to a specific formula, which has similar physical and chemical properties to physiological CSF. MACSF will be freshly made and used. It will be prepared by trained professionals on a specific workbench and sent to the patient wards in a special container. Finally, it will be used in the CSF replacement. Aseptic principles should be enforced strictly during the whole procedures, including preparation, transportation and application.
Study NCT05612854 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical embolectomy: by hydromechanical defragmentation by pigtail
Description: Hydro-mechanical defragmentation (HMD) is one of the CDT modalities for high-risk PE patients, in which rapid pigtail rotation is combined with heparinized saline injection for thrombus fragmentation
Study NCT05612854 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suction embolectomy by the Penumbra Indigo aspiration system
Description: The Penumbra Indigo aspiration system (Penumbra Inc., Alameda, CA, USA) that will be used, is an 8-Fr device and its associated tubing, pump, and separator, has the flexibility for placement in segmental branches of the pulmonary arteries.~510(k) Number :K160449 FOIA Releasable 510(k) K160449 Device Name:Penumbra System, Penumbra Pump MAX
Study NCT05537909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological sample collection
Description: All patients and their controls will be asked to provide a urine, stool, saliva and blood sample during a follow-up visit. Patients will not be specifically asked to take these samples, they will be taken during a follow-up visit, during which these samples are usually already taken.
Study NCT05293769 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: questionnaire will be filled in by all participants
Study NCT05148286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment
Description: For the treatment group, 200cc of 20% human albumin with 15 cc per kg of crystalloid will be administered over 1\~2h for initial fluid resuscitation. The treating physicians can choose the type of fluid, such as balanced fluid or isotonic saline.
Study NCT05148286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For the control group, 30 cc per kg of crystalloid will be administered according to the usual practice. The treating physicians can choose the type of fluid, such as balanced fluid or isotonic saline.
Study NCT06382168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFP-10917
Description: DFP-10917 4 mg/m\^2/day is given as a continuous 14-day intravenous infusion, followed by a 14-day rest in each 28-day cycle.
Study NCT06382168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax 400 mg once daily for 10-14 days, followed by a 14-day rest in each 28-day cycle.
Study NCT05272007 — intervention group
Intervention type: PROCEDURE
Intervention: EUS-biliary drainage
Description: EUS-GBD with LAMS
Study NCT06359652 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Prehabilitation Program (Apple Watch Series 6 with exercise flipbook)
Description: We will evaluate whether use of a personal device (the Apple Watch) could help medical professionals assess patients' pre-surgery prehab state. It will also assess whether patients are willing to use a personal device and engage in prehab exercise and whether the device can enhance prehab uptake. The intervention is to also offer patients the Exercise Flipbook, to send them a reminder to exercise and to send them notifications to track their exercise.
Study NCT04993651 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP is a form of noninvasive positive pressure ventilation (NPPV). CPAP works to maintain adequate levels of PO2 and PCO2 through improved alveolar ventilation and maintenance of upper-airway patency.
Study NCT06250699 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tubeless laparoscopic adrenalectomy
Description: No drainage tube placed after laparoscopic adrenalectomy
Study NCT06250699 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drainage tube
Description: Placing drainage tubes after laparoscopic adrenalectomy
Study NCT05924984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: perforator locator
Description: During CT scan, the patient was lying on the examination bed in a supine position, with the patient's toes facing up and fixed with an ankle fixator, the perforator was placed on the outside of the patient's thigh, and the base was extended or shortened according to the length of the patient's thigh, so that the iliac pole was located on the anterior superior spine of the patient's iliac and the patella pole was located on the lateral border of the patient's patella, and the positioning point was marked on the skin with a pen. After CT examination, the position of the perforating branch was displayed after 3D reconstruction of blood vessels by computer, and the position of the perforating branch was calculated using the computer position. The perforating branch positioning rod was moved according to the calculated scale to make it correspond to the scale, and the corresponding skin position mark was made according to the perforating branch positioning rod.
Study NCT04841863 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MyPlan digital health platform
Description: Inclusion in the active group involves the use of MyPlan digital health tool that aims to improve clinical-patient communication, enahnce patient empowerment, improve early detection of side effects and allows professionals to individualize interventions.
Study NCT04841863 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Satndard care
Description: Inclusion in the control group do not involves the use of MyPlan digital health tool. Patients will receive the standard of care.
Study NCT04588922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLS009
Description: Solution for injection
Study NCT04588922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: Tablets
Study NCT04588922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Solution for injection
Study NCT06000540 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RespirAct
Description: RespirAct device-based computer-controlled gas delivery at different concentrations as per protocol
Study NCT06046040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TmPSMA-02 CAR T Cells
Description: TmPSMA-02 CAR T cells: autologous T cells transduced with a lentiviral vector to express an anti-PSMA CAR containing a humanized J591-derived scFv and CD2 co-stimulatory domain, and dually armored with a TGFβRDN and PD1.CD28 switch receptor.
Study NCT06011759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Academic Detailing (AD)
Description: The National Resource Center for Academic Detailing (NaRCAD) describes AD as an innovative, one-on-one outreach education technique that helps clinicians provide evidence-based care to their patients. Using an accurate, up-to-date synthesis of the best clinical evidence in an engaging format, academic detailers ignite clinician behavior change, ultimately improving patient health. A successful AD visit is highly interactive, always a dialogue, and assesses a clinician's individual needs, beliefs, attitudes, issues, and concerns in order to promote better \[practice\].
Study NCT06011759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LEAP
Description: Learn. Engage. Act. Process (LEAP) program is a structured 6-month core curriculum plus 6 monthly collaborative sessions. The LEAP quality improvement program engages frontline teams in sustained incremental improvements of EBPs over a six-month period, allowing space for busy clinicians to learn and immediately apply fundamental QI skills. LEAP encompasses: 1) a structured, accessible curriculum based on the Institute for Healthcare Improvement's (IHI) Model for Improvement and Plan-Do-Study-Act cycles of change; 2) team-based, hands-on learning, and 3) coaching support and a QI network to enhance learning and accountability.
Study NCT06577181 — intervention group
Intervention type: DRUG
Intervention: hCG + estradiol
Description: Human chorionic gonadotropins
Study NCT06577181 — intervention group
Intervention type: OTHER
Intervention: Observation arm
Description: estradiol only wuithout giving hcg
Study NCT04714840 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise testing results
Description: Tailored, home-delivered aerobic and strengthening intervention,exercise intolerance,Both groups of participants will be provided with the results of their exercise testing.
Study NCT04714840 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Individually tailored exercise program (INT)
Description: Individuals randomized to receive an individually tailored exercise program will meet with an exercise specialist. Written instructions, videos of each strengthening exercise, a blue tooth enable heart rate monitor, all necessary exercise equipment, and an iPad pre-loaded with heart rate monitor software, exercise videos and ZOOM app (for video conferencing) will be provided. After returning home, the exercise specialist will supervise and provide guidance to the individual via the ZOOM app during the first 2 weeks (3 sessions per week). Supervision will slowly decrease to twice a week in weeks 3-4, once a week in weeks 5-8, every other week in weeks 9-16, and to one time midway between weeks 17-20. The exercise program will be adjusted depending on the individuals progress.
Study NCT04714840 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Generalized exercise recommendations (AC)
Description: Individuals randomized to receive the generalized exercise recommendations will receive a copy of the Physical Activity Guidelines for Americans. At the baseline visit, a study staff will review these guidelines and answer questions about their exercise testing and encourage them to be physically active. The staff will contact them via telephone to complete a short questionnaire weekly during weeks 1-8 and monthly for weeks 9-20.
Study NCT05984121 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Local ozon injections
Description: Local ozone therapy is approximately 2-3 cc of medical ozone, ozone-resistant is realised by injecting subcutaneously or intramuscularly with injectors. Local ozone injection group at 0., 2. and 4. weeks with ultrasound guided medial Firstly 1.5 cc with a 25 gauge needle into the plantar fascia insertion in the plantar region 02 lidocaine injection in a sterile way and then (according to the weeks 3 cc ozone injection of 10, 15 and 20 pyg/ml will be made respectively.
Study NCT05984121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local ozon injections
Description: Local ozone therapy is approximately 2-3 cc of medical ozone, ozone-resistant is realised by injecting subcutaneously or intramuscularly with injectors. Local ozone injection group at 0., 2. and 4. weeks with ultrasound guided medial Firstly 1.5 cc with a 25 gauge needle into the plantar fascia insertion in the plantar region 02 lidocaine injection in a sterile way and then (according to the weeks 3 cc ozone injection of 10, 15 and 20 pyg/ml will be made respectively.
Study NCT05984121 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Local dextroz prolotherapy injections
Description: Dextrose prolotherapy injection group under ultrasound guidance at weeks 0, 2 and 4 1.5 cc 30% dextrose solution and 1.5 cc 2 lidocaine mixture with a 25 gauge needle into the medial plantar region cc 2 lidocaine mixture will be made sterile with 3 cc 15% dextrose.
Study NCT05984121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local dextroz prolotherapy injections
Description: Dextrose prolotherapy injection group under ultrasound guidance at weeks 0, 2 and 4 1.5 cc 30% dextrose solution and 1.5 cc 2 lidocaine mixture with a 25 gauge needle into the medial plantar region cc 2 lidocaine mixture will be made sterile with 3 cc 15% dextrose.
Study NCT05984121 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise Group
Description: Patients will receive a conventional therapy program consisting of exercises
Study NCT05567458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Specified dose on specified days
Study NCT05567458 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study NCT06178796 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implant
Description: Dental implant placement
Study NCT05368038 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Confirmatory Testing
Description: All positive screens will be referred using standard notification procedures, where the New York State NBS reporting team contacts the ScreenPlus site medical geneticist, who will contact the newborn's pediatrician and family. The initial evaluation will include a clinical examination and confirmatory molecular studies, enzymatic and biomarker studies, when available. All aspects of the confirmatory testing will be at no cost to the participants. If confirmed to have a ScreenPlus disorder, the investigators will counsel the family and help connect them with treatment, clinical trials and disease specialists. The investigators will also provide emotional and social support resources to help in this journey.
Study NCT06423950 — intervention group
Intervention type: OTHER
Intervention: Peds Evolutionary Tumor Board (pedsETB)
Description: The pedsETB consists of evolutionary biologists, mathematicians, research scientists, statisticians, data scientists, radiologists, pathologists, oncologists (surgical, radiation, medical, and pediatric), and clinical trial coordinators. The pedsETB membership is inclusive of members from the participating institutions. The pedsETB will generate hypotheses, mathematical models, and experiments from the discussion towards further integration of evolutionary ideas towards therapeutic strategies for participants. The pedsETB will collect data through a chart review regarding adherence and results of ETB recommendation.
Study NCT05407389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KT-301 (formerly US-APR2020)
Description: KT-301 (formerly US-APR2020) will be administered orally at 2 capsules per day (a total dose of 90 Billion CFUs per day of the Live BioTherapeutic).
Study NCT06578364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Educational Program about Preconception Care
Description: The educational program consisted of a single session, which included a lecture, pictures, videos, and discussions.
Study NCT04003285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: ALLO 0 nM (placebo: loading dose, 4-hour infusion, taper)
Study NCT04003285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopregnanolone
Description: ALLO 50 nM (lower dose ALLO: loading dose, 4 hour infusion, taper)
Study NCT04003285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopregnanolone
Description: ALLO 150 nM (higher dose ALLO: loading dose, 4 hour infusion, taper)
Study NCT04590664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verteporfin
Description: Given IV
Study NCT04677647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OurChild mHealth Digital Platform
Description: The intervention being created and tested in this study is OurChild an integrated mHealth/EHR app, initially designed for the Chinese American community in Sunset Park, Brooklyn. All participants will be assigned to either beta versions undergoing development, or to version 1.0.
Study NCT06105060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg
Description: to evaluate and compare the protective outcomes of using Rosuvastatin, Vitamin E, and N-acetyl cysteine in Egyptian patients with NASH.
Study NCT06105060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin 20mg
Description: to evaluate and compare the protective outcomes of using Rosuvastatin, Vitamin E, and N-acetyl cysteine in Egyptian patients with NASH.
Study NCT06494020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task Practice combined with Transcutaneous Spinal Cord Stimulation( TcSCS)
Description: Hand rehabilitative tasks ( for gross hand movement, grasp and pinch tasks) will be done by participants during which time the participant will receive TcSCS. This will be done three times a week for 60 minutes.
Study NCT05302089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain management and shoulder bandage
Description: All Patients receive standard pain management according to the local guidelines and a sling and swathe on the day of injury. After 10 to 14 days, all patients will receive a sling for optional use for one to two weeks and be randomized after oral and written informed consent.
Study NCT05302089 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain management and shoulder bandage
Description: All Patients receive standard pain management according to the local guidelines and a sling and swathe on the day of injury. After 10 to 14 days, all patients will receive a sling for optional use for one to two weeks and be randomized after oral and written informed consent.
Study NCT05302089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One-time physiotherapy instruction
Description: Patients are offered a one-time physiotherapy instruction about the course of pain and suggestions for quick and safe return to activities of daily living within the first three months post-injury.
Study NCT05302089 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One-time physiotherapy instruction
Description: Patients are offered a one-time physiotherapy instruction about the course of pain and suggestions for quick and safe return to activities of daily living within the first three months post-injury.
Study NCT05302089 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual rehabilitation care
Description: At the visit 10-14 days after the injury, the orthopaedic consultant (senior author SB) will refer the patient to usual rehabilitation care with a physiotherapist in a municipality close to the patient´s home. The physiotherapist then schedules the start date, typically three weeks after the injury. The rehabilitation content and duration is planned according to the choice of the local treating physiotherapist in consultation with the patient.
Study NCT04830137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-2127
Description: Oral NX-2127
Study NCT04773951 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS004, a recombinant humanized, IgG4κ monoclonal antibody (mAb) specific to B- and T-lymphocyte attenuator (BTLA); Toripalimab Injection
Description: Biological: JS004, Intravenous infusion; Toripalimab Injection, Intravenous infusion
Study NCT05696236 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transepidermal water loss (TEWL) monitor and stopping rules
Description: The oral food challenge will be done as usual, and participants will wear the TEWL monitor. The research food allergy nurse and doctor will also be looking for signs and symptoms of an allergic reaction. The research study coordinator will be watching the TEWL numbers. If they numbers match the stopping rules, they will tell the doctor and the oral food challenge will be over.
Study NCT05696236 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monitor (TEWL) without stopping rules
Description: The oral food challenge will be done as usual, and participants will wear the TEWL monitor. The research food allergy nurse and doctor will be looking for signs and symptoms of an allergic reaction. The research study coordinator will be watching the TEWL numbers, but the stopping rules will not be used to end the oral food challenge.
Study NCT05678608 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical excision
Description: posterior midline approach and total excision for spinal cord tumors
Study NCT06331559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0501 Tablets
Description: Every 28 days is one cycle. Multiple dose levels of SIM0501 will be explored in dose escalation, and determine the maximum tolerated dose.
Study NCT06331559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0501 Tablets
Description: Every 28 days is one cycle.Patients will be administered a potential recommended dose of SIM0501 established from SIM0501 mono dose escalation.
Study NCT06331559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0501 in combination with olaparib
Description: Every 28 days is one cycle.Multiple dose levels of SIM0501 and olaparib will be explored in dose escalation, and determine the maximum tolerated dose.
Study NCT06331559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0501 in combination with olaparib
Description: Every 28 days is one cycle.Patients will be administered a potential recommended dose of SIM0501 combination with olaparib established from SIM0501 combination dose escalation.
Study NCT05620667 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: immature ponkan (Citrus reticulate) extract
Description: Drink 25mL for once, and once a day.
Study NCT05620667 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Drink 25mL for once, and once a day.
Study NCT05620667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: time restricted feeding
Description: Controlling a shortened period of time for eating within 8 hour each day.